Vaginal DNA Assay Shows Promise
A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.
By
Kerri Miller
May 8, 2026
Clinical Scorecard: Vaginal DNA Assay Shows Promise
At a Glance
Category Detail
Condition Key Mechanisms Target Population Women aged 45 years and older with abnormal uterine bleeding, and younger patients with specific risk factors. Care Setting
Key Highlights
96% sensitivity and 82% specificity for detecting endometrial cancer (from a case-control study, not directly applicable to clinical rule-out). Utilizes self-collected vaginal fluid samples via unscented tampons. Addresses limitations of current diagnostic methods like endometrial biopsy and dilation and curettage. Guideline-Based Recommendations
Diagnosis
Endometrial sampling recommended for patients aged 45 and older with abnormal uterine bleeding. Management
Further validation in real-world populations needed before clinical implementation. Monitoring & Follow-up
Assess negative predictive value in broader populations. Risks
Current diagnostic methods carry procedural burdens and risks. Patient & Prescribing Data
Assay shows promise but requires further validation before clinical use.
Clinical Best Practices
Consider the assay as a supplementary tool pending further validation. Use existing guidelines for endometrial sampling in appropriate patient populations. Related Resources & Content
